Skip to main content

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Research lines

Detección precoz de cáncer mamario antes de que éste se manifieste

A partir de datos preliminares de arrays, hemos caracterizado algunos microRNAs/mRNAs relevantes en tumores. Actualmente los estamos analizando a nivel de pacientes con cáncer en sangre como posible método predictivo antes de la aparición del tumor.

IP: Matilde Lleonart Pajarin

Projects

Ayudas Margarita Salas

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Judit Álvarez González
Funding agency: Ministerio de Universidades
Funding: 0.01
Reference: MIU/M_SALAS/2021/GARCIA_UB
Duration: 01/04/2022 - 31/03/2022

Novel terapéutic approaches against COVID-19

IP: Matilde Lleonart Pajarin
Collaborators: Marina Bataller Fernández, Almudena Sanchez Garcia, Yoelsis Garcia Mayea
Funding agency: Fundació La Marató de TV3
Funding: 161875
Reference: 202116
Duration: 23/09/2021 - 22/09/2024

New therapeutic approaches in head and neck cancer

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Jordi Temprana Salvador, Angel García Jiménez, Josep Castellví Vives, Laia Josa Culleré, Marina Bataller Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI20/00556
Duration: 01/01/2021 - 30/06/2025

Drug-screen against novel proteins involved in cancer resistance

IP: Matilde Lleonart Pajarin
Collaborators: Almudena Sanchez Garcia, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2019/SANCHEZ
Duration: 14/09/2020 - 13/09/2023

Related news

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

The work has compared sensitive and resistant cells to cisplatin treatment to understand the mechanisms involved in resistance and to find new biomarkers and therapies.

Related professionals

Cristina Vetoret Vázquez

Cristina Vetoret Vázquez

Research assistant
Clinical Neuroimmunology
Read more
Melissa Bradbury Lobato

Melissa Bradbury Lobato

Biomedical Research in Gynaecology
Read more
Norberto Núñez Seral

Norberto Núñez Seral

Tècnic/a Superior Recerca
High Technology Unit (UAT)
Preclinical Core Facilities
Core Facilities Area
Read more
María  Puigcerver  Mas

María Puigcerver Mas

Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.